| Identification | Back Directory | [Name]
4-(1-(2-amino-5-chloropyrimidin-4-yl)-2-(thiaol-2-yl)but-30-yn-2-ol | [CAS]
1202764-53-1 | [Synonyms]
B022
4-(1-(2-amino-5-chloropyrimidin-4-yl)-2-(thiaol-2-yl)but-30-yn-2-ol
2-Thiazolemethanol, α-[2-[1-(2-amino-5-chloro-4-pyrimidinyl)-2,3-dihydro-1H-indol-6-yl]ethynyl]-α-methyl- | [Molecular Formula]
C19H16ClN5OS | [MDL Number]
MFCD32645350 | [MOL File]
1202764-53-1.mol | [Molecular Weight]
397.88 |
| Chemical Properties | Back Directory | [Boiling point ]
644.4±65.0 °C(Predicted) | [density ]
1.53±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (628.33 mM) | [form ]
Solid | [pka]
10.71±0.29(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Biological Activity]
B022 is a potent and selective NF-κB-inducible kinase (NIK) inhibitor with Ki of 4.2 nM. B022 protects the liver from inflammation, oxidative stress and damage caused by toxins. | [in vitro]
B022 (0-5 μM; 12 hours; Hepa1 cells) treatment suppresses NIK-induced p52 formation in a dose-dependent manner.
B022 (0-5 μM; 12 hours; Hepa1 cells) treatment for 8 h completely blocks NIK-induced expression of TNF-a, IL-6, iNOS, CCL2, and CXCL5. Western Blot Analysis | Cell Line: | Hepa1 cells | | Concentration: | 0 μM, 0.5 μM, 5 μM | | Incubation Time: | 12 hours | | Result: | Suppressed NIK-induced p52 formation in a dose-dependent manner. | td> | RT-PCR | Cell Line: | Hepa1 cells | | Concentration: | 0 μM, 0.5 μM, 5 μM | | Incubation Time: | 12 hours | | Result: | Dose-dependently blocked NIK-induced expression of chemokines, cytokines, and iNOS in these cells. Completely blocked NIK-induced expression of TNF-a, IL-6, iNOS, CCL2, and CXCL5. | < /span> | [in vivo]
B022 (30 mg/kg; intravenous injection; twice a day; for 10 days; STOP-NIK male mice) treatment inhibits NIK-triggered liver inflammation and injury in STOP-NIK mice infected with cre adenoviruses. < /p> < tr> | Animal Model: | STOP-NIK male mice (8 weeks) infected with Ad-cre | | Dosage: | 30 mg/kg | | Administration: | Intravenous injection; twice a day; for 10 days | | Result: | Completely prevents the lethal effect of abnormally high levels of hepatic NIK in mice. Inhibited the majority of the deteriorating effects of aberrant activation of hepatic NIK. | | [target]
Ki: 4.2 nM (NF-κB-inducing kinase (NIK)) |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
http://www.weikeqi-biotech.com/ |
|